M&T Bank Corp Trims Stake in Boston Scientific Corporation $BSX

Key Points

• M&T Bank Corp reduced its stake in Boston Scientific by 74.5% in Q4, selling 60,258 shares and leaving 20,641 shares valued at about $1.97 million.
• CEO Michael F. Mahoney sold 160,901 shares at an average price of $93.49 (≈$15.04M), cutting his ownership by 10.23%.
• Shares face significant pressure from analyst price‑target cuts, a depressed share price near a 52‑week low, and numerous class‑action filings that raise near‑term legal uncertainty.

M&T Bank Corp reduced its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 74.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,641 shares of the medical equipment provider's stock after selling 60,258 shares during the period. M&T Bank Corp's holdings in Boston Scientific were worth $1,968,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BSX. Vanguard Group Inc. boosted its position in shares of Boston Scientific by 0.8% in the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider's stock worth $13,497,294,000 after purchasing an additional 1,115,337 shares during the period. Rathbones Group PLC boosted its position in shares of Boston Scientific by 20.9% in the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider's stock worth $263,133,000 after purchasing an additional 477,680 shares during the period. Synergy Asset Management LLC boosted its position in shares of Boston Scientific by 3,493.0% in the third quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider's stock worth $48,297,000 after purchasing an additional 479,593 shares during the period. Gladstone Institutional Advisory LLC boosted its position in shares of Boston Scientific by 39.5% in the third quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider's stock worth $5,065,000 after purchasing an additional 14,700 shares during the period. Finally, Kepler Cheuvreux Suisse SA bought a new position in shares of Boston Scientific in the third quarter worth approximately $26,955,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. BTIG Research dropped their price target on shares of Boston Scientific from $90.00 to $80.00 and set a "buy" rating for the company in a research report on Wednesday, April 22nd. Jefferies Financial Group dropped their price target on shares of Boston Scientific from $110.00 to $100.00 and set a "buy" rating for the company in a research report on Wednesday, April 22nd. The Goldman Sachs Group dropped their price target on shares of Boston Scientific from $87.00 to $84.00 and set a "buy" rating for the company in a research report on Wednesday, April 22nd. Evercore dropped their price target on shares of Boston Scientific from $112.00 to $96.00 and set an "outperform" rating for the company in a research report on Thursday, February 5th. Finally, Stifel Nicolaus dropped their price target on shares of Boston Scientific from $90.00 to $85.00 and set a "buy" rating for the company in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $93.91.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares of the company's stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.34% of the company's stock.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Heart Rhythm 2026 clinical data: Boston Scientific reported favorable trial results for its FARAPULSE PFA platform and WATCHMAN FLX LAAC (superiority vs antiarrhythmics for persistent AF, plus positive safety/effectiveness outcomes) — data that supports growth in electrophysiology and stroke‑care franchises. Boston Scientific Trial Wins Highlight Growth Potential In Electrophysiology And Stroke Care
• Neutral Sentiment: Valuation/opportunistic commentary: Some analysts and outlets argue BSX’s share price and valuation now look attractive after the decline, suggesting potential for a rebound if execution and integration issues are resolved. This is an investor‑opinion piece rather than new operational data. Massively Disappointing Boston Scientific (BSX) Stock Could Be Due for a Comeback
• Negative Sentiment: Broad surge of securities‑fraud notices and lead‑plaintiff solicitations: Multiple law firms have filed/announced class actions and are soliciting BSX investors who bought shares between July 23, 2025 and Feb 3, 2026; firms are urging claims and reminding investors of the May 4 lead‑plaintiff deadline — this increases legal risk, potential litigation costs and near‑term uncertainty. BSX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
• Negative Sentiment: Analyst downgrades, 52‑week low and deal concerns: Coverage notes that analysts have trimmed targets after a guidance reduction and issues tied to the Penumbra transaction, and BSX hit a 52‑week low — these factors are pressuring the stock and investor sentiment. Boston Scientific (BSX) Stock Plunges to 52-Week Low: Analyst Downgrades Pile Up
• Negative Sentiment: Multiple law‑firm notices and related allegations: Additional firms (Rosen, Pomerantz, Bronstein, Portnoy, Bernstein, Gross, etc.) have issued alerts and filings alleging misstated outlooks or concealed weak U.S. electrophysiology sales — amplifies reputational and legal overhang. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSX

Boston Scientific Trading Down 2.5%

Shares of BSX opened at $58.46 on Wednesday. Boston Scientific Corporation has a twelve month low of $58.02 and a twelve month high of $109.50. The company has a market cap of $86.88 billion, a P/E ratio of 24.46, a P/E/G ratio of 1.10 and a beta of 0.78. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The company's fifty day simple moving average is $67.80 and its 200-day simple moving average is $85.11.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter in the prior year, the firm posted $0.75 earnings per share. The business's revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts expect that Boston Scientific Corporation will post 3.38 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.